Zacks Research Analysts Lower Earnings Estimates for BIO

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research lowered their Q1 2025 earnings estimates for shares of Bio-Rad Laboratories in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.34 for the quarter, down from their previous estimate of $2.57. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2025 earnings at $2.87 EPS, Q3 2025 earnings at $2.94 EPS and Q3 2026 earnings at $2.90 EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Citigroup boosted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada boosted their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and a consensus target price of $391.80.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded up $7.33 during midday trading on Friday, reaching $332.91. The company had a trading volume of 183,485 shares, compared to its average volume of 245,915. The company's 50 day moving average price is $340.38 and its 200 day moving average price is $315.33. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a market cap of $9.32 billion, a P/E ratio of -11.93 and a beta of 0.93. Bio-Rad Laboratories has a 52-week low of $262.12 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.33 EPS.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Avior Wealth Management LLC grew its holdings in shares of Bio-Rad Laboratories by 3.3% during the third quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company's stock worth $334,000 after purchasing an additional 32 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Wahed Invest LLC boosted its stake in Bio-Rad Laboratories by 14.0% in the first quarter. Wahed Invest LLC now owns 399 shares of the medical research company's stock worth $138,000 after buying an additional 49 shares in the last quarter. Capital Advisors Ltd. LLC boosted its stake in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after buying an additional 62 shares in the last quarter. Finally, Natixis boosted its stake in Bio-Rad Laboratories by 3.4% in the first quarter. Natixis now owns 1,986 shares of the medical research company's stock worth $687,000 after buying an additional 65 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Insider Activity at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP James Barry sold 623 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. This represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by company insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.